Study Title

[68Ga]Ga-FAPI-46 PET/CT in Early Detection of Lymph Node Metastasis in Head and Neck Squamous Cell Carcinomas

Study Details

Description:

In this research endeavor, the primary objective is to highlight the additional value of [68Ga]Ga-FAPI-46 PET/CT into the standard pre-surgical imaging protocol.

Sponsor:

John O. Prior, MD, Ph.D.

Contacts:

John O Prior, MD, PhD

john.prior@chuv.ch

+41 21 314 4348

Government Study Link:

NCT06794372 - Click here to see study on

ClinicalTrials.gov

Drug Details

[68Ga]Ga-FAPI-46
Isotope(s):
    GALLIUM-68
    Radioisotope: Ga-68
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 68 minutes
    Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
    Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
    Range: N/A
    Decay Daughters: Zn68 (Stable)
    Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
  • GALLIUM-68
Target(s):
  • FAP

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468